Biogen (NASDAQ:BIIB) Releases FY 2025 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.250-16.250 for the period, compared to the consensus estimate of 16.240. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

BIIB has been the topic of several analyst reports. Sanford C. Bernstein began coverage on Biogen in a research report on Tuesday. They set a “market perform” rating and a $160.00 target price on the stock. Canaccord Genuity Group reduced their target price on shares of Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday. Robert W. Baird raised their target price on shares of Biogen from $294.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. Scotiabank cut their price target on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating on the stock in a report on Thursday. Finally, Bank Of America (Bofa) dropped their target price on Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a research report on Tuesday. Seventeen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $211.96.

Biogen Trading Up 1.7 %

Shares of Biogen stock opened at $140.83 on Friday. Biogen has a 12-month low of $128.51 and a 12-month high of $238.00. The firm’s 50 day simple moving average is $147.31 and its two-hundred day simple moving average is $173.80. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $20.52 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 1.65 and a beta of -0.08.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%. Analysts predict that Biogen will post 16.42 EPS for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.